ALK-Abello A/S
F:4AJ0

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
F:4AJ0
Watchlist
Price: 29.42 EUR -1.14% Market Closed
Market Cap: €5.9B

Net Margin

18.1%
Current
Improving
by 5.9%
vs 3-y average of 12.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
18.1%
=
Net Income
kr1.1B
/
Revenue
kr6.1B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
18.1%
=
Net Income
€1.1B
/
Revenue
kr6.1B

Peer Comparison

Country Company Market Cap Net
Margin
DK
ALK-Abello A/S
CSE:ALK B
48.6B DKK
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

Higher than 75% of companies in Denmark
Percentile
75th
Based on 559 companies
75th percentile
18.1%
Low
-18 280.1% — 1.4%
Typical Range
1.4% — 15.8%
High
15.8% — 2 389.6%
Distribution Statistics
Denmark
Min -18 280.1%
30th Percentile 1.4%
Median 3.9%
70th Percentile 15.8%
Max 2 389.6%

ALK-Abello A/S
Glance View

Market Cap
5.9B EUR
Industry
Pharmaceuticals

ALK-Abelló A/S is a fascinating player in the global pharmaceutical market, renowned for its dedication to alleviating the impact of allergies through innovative treatments. Born in the heart of Denmark, this company has carved a niche for itself by focusing intensely on developing immunotherapy solutions for allergy sufferers—a sector often overshadowed by more glamorous pharmaceutical pursuits. ALK-Abelló operates at the forefront of the allergen immunotherapy landscape, committed to transforming the lives of those affected by allergic conditions, such as hay fever and allergic asthma. The company's portfolio includes allergy immunotherapy tablets, injection-based treatments, and diagnostic devices designed to offer comprehensive allergy solutions, catering to both established and emerging markets. The essence of ALK-Abelló’s business model lies in its strategic focus on the research, development, and commercialization of allergy immunotherapies. Through rigorous scientific research and development, the company has developed a series of groundbreaking allergy tablets that provide patients with a convenient, effective alternative to traditional injection-based treatments. This innovation not only harnesses scientific advancements but also addresses consumer demand for ease and efficacy. Revenue streams are predominantly generated through the sale of these innovative products to healthcare providers and patients, a process supported by strong partnerships with clinical professionals and an extensive distribution network. In essence, ALK-Abelló finds its competitive edge in delivering tailored, cutting-edge allergy treatments that not only improve patient outcomes but also promise to reduce the long-term economic burden of allergic diseases.

4AJ0 Intrinsic Value
26.77 EUR
Overvaluation 9%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
18.1%
=
Net Income
kr1.1B
/
Revenue
kr6.1B
What is ALK-Abello A/S's current Net Margin?

The current Net Margin for ALK-Abello A/S is 18.1%, which is above its 3-year median of 12.2%.

How has Net Margin changed over time?

Over the last 3 years, ALK-Abello A/S’s Net Margin has increased from 7.6% to 18.1%. During this period, it reached a low of 7.3% on Mar 31, 2023 and a high of 18.1% on Sep 30, 2025.

Back to Top